394 related articles for article (PubMed ID: 14670123)
1. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
2. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors.
Everett RS; Evans HK; Hodges BL; Ding EY; Serra DM; Amalfitano A
Virology; 2004 Jul; 325(1):96-105. PubMed ID: 15231389
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve.
Jani A; Menichella D; Jiang H; Chbihi T; Acsadi G; Shy ME; Kamholz J
Hum Gene Ther; 1999 Mar; 10(5):787-800. PubMed ID: 10210146
[TBL] [Abstract][Full Text] [Related]
5. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS
J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984
[TBL] [Abstract][Full Text] [Related]
6. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
8. Investigation of effects of anesthesia and age on aspiration in mice through LacZ gene transfer by recombinant E1-deleted adenovirus vectors.
Teramoto S; Matsuse T; Oka T; Ito H; Fukuchi Y; Ouchi Y
Am J Respir Crit Care Med; 1998 Dec; 158(6):1914-9. PubMed ID: 9847286
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.
Christ M; Louis B; Stoeckel F; Dieterle A; Grave L; Dreyer D; Kintz J; Ali Hadji D; Lusky M; Mehtali M
Hum Gene Ther; 2000 Feb; 11(3):415-27. PubMed ID: 10697116
[TBL] [Abstract][Full Text] [Related]
11. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
12. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies.
Mori K; Gehlbach P; Ando A; Wahlin K; Gunther V; McVey D; Wei L; Campochiaro PA
Invest Ophthalmol Vis Sci; 2002 May; 43(5):1610-5. PubMed ID: 11980881
[TBL] [Abstract][Full Text] [Related]
13. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
14. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
15. Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors.
Okuyama T; Li XK; Funeshima N; Fujino M; Sasaki K; Kita Y; Kosuga M; Takahashi M; Saito H; Suzuki S; Yamada M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S113-8. PubMed ID: 9792044
[TBL] [Abstract][Full Text] [Related]
16. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.
Mitchell M; Jerebtsova M; Batshaw ML; Newman K; Ye X
Gene Ther; 2000 Dec; 7(23):1986-92. PubMed ID: 11175309
[TBL] [Abstract][Full Text] [Related]
17. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice.
Hu H; Serra D; Amalfitano A
Hum Gene Ther; 1999 Feb; 10(3):355-64. PubMed ID: 10048388
[TBL] [Abstract][Full Text] [Related]
18. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
19. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
20. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
